Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PROP-60 is a pediatric pharmaceutical product developed by Adwin Life Care, available in formulations such as oral drops and suspension. It is a fixed-dose combination containing **paracetamol** (acetaminophen), **phenylephrine hydrochloride**, and **chlorpheniramine maleate** (chlorphenamine). Paracetamol serves as an analgesic and antipyretic, effectively reducing fever and relieving body aches by inhibiting prostaglandin synthesis in the central nervous system. Phenylephrine hydrochloride acts as a selective alpha-1 adrenergic receptor agonist, functioning as a nasal decongestant by constricting blood vessels in the nasal passages to reduce swelling and mucus congestion. Chlorpheniramine maleate is a first-generation antihistamine that antagonizes H1 receptors, providing relief from allergic symptoms such as a runny nose, sneezing, and itchy or watery eyes. PROP-60 is primarily indicated for the symptomatic management of the common cold, influenza, and upper respiratory allergies in children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + phenylephrine + chlorphenamine.